Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
This article was originally published in Pharmaceutical Approvals Monthly
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.
You may also be interested in...
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
The VEGF2-inhibitor demonstrated an overall survival benefit and prolonged progression-free survival in second-line gastric cancer, Lilly said. The big pharma acquired ramucirumab through its $6.5 billion purchase of ImClone Systems in 2008.
Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.